These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34814227)

  • 1. Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.
    Stone L; Merriman E; Hanna M; Royle G; Chan H
    Thromb Haemost; 2022 Jul; 122(7):1096-1103. PubMed ID: 34814227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials.
    Dai JW; Wang CH; Chu CL; Liao SC
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241113
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre.
    Wheeler M; Borrie A; Dookia R; Carter J
    Intern Med J; 2019 Oct; 49(10):1316-1320. PubMed ID: 31602769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
    Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
    Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
    Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Royle G; Sellke FW; Stangier J; Steiner T; Verhamme P; Wang B; Young L; Weitz JI
    N Engl J Med; 2017 Aug; 377(5):431-441. PubMed ID: 28693366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.